GKOS News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

GK

Mkt Cap

$9.73B

Volume

813.43K

Next Earnings

October 28th

Loading chart

GK

GKOSGlaukos Corporation

GKOS

Pay with—

Available Balance0.00

GK

Mkt Cap

$9.77B

Volume

813.43K

Next Earnings

October 28th

Chart Financials Earnings News About Insider Filings

Glaukos Stock Gains 36.8% in 6 Months: What's Behind the Rally?Glaukos Corporation (GKOS) shares have gained 36.8% over six months, outperforming its industry, driven by strong Q2 results with 50% revenue growth to $185.6 million, successful commercial expansion of Epioxa for keratoconus treatment, positive clinical data for iDose TR, and pipeline advances including a new retinal disease licensing agreement. The company raised its 2026 revenue guidance to $680-$700 million.Zacks Investment Research · Oct 14, 2026

Glaukos Strengthens Retinal Pipeline Through RevOpsis Licensing DealGlaukos Corporation announced a licensing agreement with RevOpsis Therapeutics to develop RO-104, a first-in-class tri-specific biologic for retinal diseases, and gained exclusive access to the RevMod platform for up to four additional retinal biologic candidates. Despite the strategic expansion, GKOS stock declined 6.3% following the announcement, though it has gained 42.8% year-to-date.Zacks Investment Research · Oct 9, 2026

Can ISRG's Single-Port Platform Become the Next Billion-Dollar Franchise?Intuitive Surgical's single-port (SP) platform is emerging as a significant growth franchise with 61% year-over-year procedure growth and an installed base of 445 systems. Strong U.S. utilization gains (25% YoY) and expanding stapler adoption (nearly 60% of eligible cases) support the platform's trajectory toward becoming a billion-dollar business. The company is also expanding internationally and through product innovation.Zacks Investment Research · Oct 7, 2026

Why Is ISRG Investing More Aggressively in R&D Despite Macro Headwinds?Intuitive Surgical is prioritizing R&D investment over near-term profitability to drive long-term growth, focusing on AI/ML, robotics, and expanding into new clinical areas like GI, cardiac, and lung procedures. The company is sacrificing near-term expense leverage to build competitive moats and broaden its addressable market. Peer companies Edwards Lifesciences and Glaukos are similarly investing heavily in R&D to strengthen their competitive positions.Zacks Investment Research · Sep 1, 2026

Glaukos CFO Alex Thurman Sells $1.6 Million in Stock. What Should Investors Do Now?Glaukos CFO Alex Thurman sold 10,000 shares worth $1.6 million on July 9, 2026, under a pre-established Rule 10b5-1 trading plan adopted in December 2025. While insider sales can raise concerns, the non-discretionary nature of this transaction and Glaukos' strong growth outlook—including 25% projected revenue growth for 2026 and the promising Epioxa product—suggest the sale does not indicate trouble for the company.The Motley Fool · Jul 14, 2026

Abbott Labs vs. Glaukos: Which Healthcare Stock Is a Better Buy in 2026?Abbott Laboratories and Glaukos represent two contrasting healthcare investment strategies: Abbott offers stability through diversification, strong profitability, and recent acquisitions like Exact Sciences, while Glaukos provides high-growth potential in specialized ophthalmic treatments with innovative products like iDose and Epioxa. Abbott trades at a lower valuation multiple but faces integration challenges and legal risks, while Glaukos shows rapid 32% revenue growth but remains unprofitable and dependent on a single manufacturing location.The Motley Fool · Jul 8, 2026

Presbyopia Market to Witness Accelerated Growth at a CAGR of 4.9% During the Forecast Period (2026–2036) Supported by Expanding Treatment Landscape | DelveInsightThe presbyopia market is projected to grow at a CAGR of 4.9% from 2026-2036, driven by an aging global population and expanding treatment options. The market was valued at USD 11 billion in 2025 across seven major markets, with the US accounting for 50% of the market. Multiple emerging therapies and devices are expected to enter the market, including Phentolamine, MicroLine, GLK-302, and CorVision, alongside already-approved treatments like VUITY, QLOSI, VIZZ, and YUVEZZI.GlobeNewswire Inc. · May 11, 2026

Nicox prévoit de rembourser intégralement ses dettes financières, NCX 470 ayant été dé-risqué et licencié dans le monde entierNicox plans to fully repay its financial debts by 2026 after successfully licensing NCX 470 globally with Kowa and Ocumension Therapeutics, with New Drug Application submissions expected in the first half of 2026 in the US and later in China.GlobeNewswire Inc. · Sep 4, 2025

Nicox Expects to Fully Repay Financial Debts with NCX 470 De-Risked and Globally LicensedNicox anticipates fully repaying its financial debts in 2026 following successful NCX 470 clinical trials and global licensing deals with Kowa and Ocumension Therapeutics, with expected NDA submissions in the U.S. and China in H1 2026.GlobeNewswire Inc. · Sep 4, 2025

Glaukos Stocks Rides on Strong Product Demand Amid CompetitionGlaukos Corporation is focused on developing and commercializing surgical devices and pharmaceutical therapies for glaucoma treatment. The company's iStent product line and global glaucoma and Corneal Health franchises are performing well, despite competition and supply chain challenges. Glaukos is also advancing its pipeline, including iDose TREX, iDose ROCK, and iLution Travoprost.Benzinga · Sep 11, 2024

to start trading

GK

GKOSGlaukos Corporation

GKOS

Pay with—

Available Balance0.00

Your PositionYou don't own any GKOS yet.

Related Tickers

Earnings